Yield10 Bioscience Q1 2024 Adj EPS $(4.77) Misses $(2.64) Estimate, Sales $300.00K Miss $1.88M Estimate
Portfolio Pulse from Benzinga Newsdesk
Yield10 Bioscience (NASDAQ:YTEN) reported Q1 2024 adjusted EPS of $(4.77), missing the $(2.64) estimate by 80.68%. Sales were $300K, missing the $1.88M estimate by 84%. Despite the misses, sales increased 400% from $60K last year.
May 15, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Yield10 Bioscience reported significant misses in both EPS and sales for Q1 2024, with EPS at $(4.77) missing the $(2.64) estimate by 80.68% and sales at $300K missing the $1.88M estimate by 84%. Despite the misses, sales increased 400% YoY.
The significant misses in both EPS and sales are likely to negatively impact the stock price in the short term. However, the 400% YoY increase in sales may provide some positive sentiment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100